Allelotype of pancreatic adenocarcinoma using xenograft enrichment - PubMed (original) (raw)
. 1995 Oct 15;55(20):4670-5.
Affiliations
- PMID: 7553647
Allelotype of pancreatic adenocarcinoma using xenograft enrichment
S A Hahn et al. Cancer Res. 1995.
Abstract
p53 and MTS1 are known to be mutationally inactivated in pancreatic adenocarcinoma. Other tumor suppressor genes are likely also to play a role. To define chromosomal arms which may harbor additional tumor suppressor genes, we performed an extensive allelotype on pancreatic cancer utilizing a xenograft enrichment technique. Eighty-eight percent (28/32) of primary tumors gave rise to xenografts. Eighteen cases were used in a PCR-based allelotype using 283 polymorphic markers, over 2800 informative assays, and an average coverage of 4.1 informative markers per chromosomal arm per case. Highly frequent allelic loss (> 60%) was seen at chromosomes 1p, 9p, 17p, and 18q. Moderately frequent allelic loss (40-60%) was seen at 3p, 6p, 6q, 8p, 10q, 12q, 13q, 18p, 21q, and 22q. The average fractional allelic loss was 0.36. Allelic and sequence stability was demonstrated among 64 parallel and second-passage xenografts derived from 12 cases of pancreatic adenocarcinoma with the ascertainment of over 3000 single alleles. The findings were confirmed in primary tumors. In only two instances were discrepancies revealed between the allelic loss data obtained from corresponding parallel xenografts, probably due to the xenografting of minor subpopulations, reflecting genetic heterogeneity of the primary tumor.
Similar articles
- Allelotype analysis of childhood acute lymphoblastic leukemia.
Takeuchi S, Bartram CR, Wada M, Reiter A, Hatta Y, Seriu T, Lee E, Miller CW, Miyoshi I, Koeffler HP. Takeuchi S, et al. Cancer Res. 1995 Nov 15;55(22):5377-82. Cancer Res. 1995. PMID: 7585604 - Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma.
Yatsuoka T, Sunamura M, Furukawa T, Fukushige S, Yokoyama T, Inoue H, Shibuya K, Takeda K, Matsuno S, Horii A. Yatsuoka T, et al. Am J Gastroenterol. 2000 Aug;95(8):2080-5. doi: 10.1111/j.1572-0241.2000.02171.x. Am J Gastroenterol. 2000. PMID: 10950061 - Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a I-cM region of common allelic loss.
Kimura M, Abe T, Sunamura M, Matsuno S, Horii A. Kimura M, et al. Genes Chromosomes Cancer. 1996 Oct;17(2):88-93. doi: 10.1002/(SICI)1098-2264(199610)17:2<88::AID-GCC3>3.0.CO;2-X. Genes Chromosomes Cancer. 1996. PMID: 8913725 - Familial pancreatic cancer and the genetics of pancreatic cancer.
Lumadue JA, Griffin CA, Osman M, Hruban RH. Lumadue JA, et al. Surg Clin North Am. 1995 Oct;75(5):845-55. doi: 10.1016/s0039-6109(16)46731-9. Surg Clin North Am. 1995. PMID: 7660249 Review. - Molecular genetics of exocrine pancreatic neoplasms.
Hahn SA, Kern SE. Hahn SA, et al. Surg Clin North Am. 1995 Oct;75(5):857-69. doi: 10.1016/s0039-6109(16)46732-0. Surg Clin North Am. 1995. PMID: 7660250 Review.
Cited by
- Meningioma animal models: a systematic review and meta-analysis.
Andersen MS, Kofoed MS, Paludan-Müller AS, Pedersen CB, Mathiesen T, Mawrin C, Wirenfeldt M, Kristensen BW, Olsen BB, Halle B, Poulsen FR. Andersen MS, et al. J Transl Med. 2023 Oct 28;21(1):764. doi: 10.1186/s12967-023-04620-7. J Transl Med. 2023. PMID: 37898750 Free PMC article. - Large-Scale Proteomics Data Reveal Integrated Prognosis-Related Protein Signatures and Role of SMAD4 and RAD50 in Prognosis and Immune Infiltrations of Prostate Cancer Microenvironment.
Anwaier A, Zhu SX, Tian X, Xu WH, Wang Y, Palihati M, Wang WY, Shi GH, Qu YY, Zhang HL, Ye DW. Anwaier A, et al. Phenomics. 2022 Sep 27;2(6):404-418. doi: 10.1007/s43657-022-00070-1. eCollection 2022 Dec. Phenomics. 2022. PMID: 36939777 Free PMC article. - A renal cell carcinoma tumorgraft platform to advance precision medicine.
Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. Elias R, et al. Cell Rep. 2021 Nov 23;37(8):110055. doi: 10.1016/j.celrep.2021.110055. Cell Rep. 2021. PMID: 34818533 Free PMC article. - Targeting loss of heterozygosity for cancer-specific immunotherapy.
Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Hwang MS, et al. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022410118. doi: 10.1073/pnas.2022410118. Proc Natl Acad Sci U S A. 2021. PMID: 33731480 Free PMC article. - CD36 and CD97 in Pancreatic Cancer versus Other Malignancies.
Tanase C, Gheorghisan-Galateanu AA, Popescu ID, Mihai S, Codrici E, Albulescu R, Hinescu ME. Tanase C, et al. Int J Mol Sci. 2020 Aug 6;21(16):5656. doi: 10.3390/ijms21165656. Int J Mol Sci. 2020. PMID: 32781778 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous